fbpx

Day

June 13, 2016
NMD Pharma develops new treatments, improving the signaling of the nerves to the muscles, to patients suffering from orphan motor neuron diseases including Myasthenia Gravis, Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). The company has identified a novel disease target and developed new small molecule drug-like compounds effectively increasing neuromuscular transmission. In models...

News

Professor wants to develop a radioactive precision missile to target brain cancer
21. February 2020
New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge